Profile data is unavailable for this security.
About the company
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
- Revenue in USD (TTM)90.63bn
- Net income in USD22.66bn
- Incorporated1887
- Employees138.10k
- LocationJohnson & JohnsonOne Johnson & Johnson PlazaNEW BRUNSWICK 08933United StatesUSA
- Phone+1 (732) 524-2455
- Fax+1 (732) 214-0332
- Websitehttps://www.jnj.com/
Mergers & acquisitions
| Acquired company | JNJ:NYQ since announced | Transaction value |
|---|---|---|
| Intra-Cellular Therapies Inc | 15.23% | 14.63bn |
| V-Wave Ltd | 2.55% | 1.70bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | 47.64bn | 5.42bn | 97.81bn | 34.10k | 18.04 | 5.62 | 7.24 | 2.05 | 2.66 | 2.66 | 23.44 | 8.54 | 0.4976 | 4.27 | 5.12 | 1,396,950.00 | 5.68 | 0.6536 | 7.69 | 0.8175 | 74.69 | 76.63 | 11.41 | 1.52 | 1.17 | 7.39 | 0.7402 | 678.24 | 7.32 | 13.06 | -211.50 | -- | 8.34 | 7.91 |
| Vertex Pharmaceuticals Inc | 11.10bn | -988.90m | 118.97bn | 6.10k | -- | 7.22 | -- | 10.72 | -3.88 | -3.88 | 42.86 | 64.20 | 0.4744 | 1.43 | 6.17 | 1,819,623.00 | -4.23 | 14.06 | -5.04 | 16.67 | 86.03 | 87.35 | -8.91 | 26.28 | 2.29 | -- | 0.0067 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Gilead Sciences Inc | 28.74bn | 5.97bn | 135.34bn | 17.60k | 23.01 | 7.07 | 15.49 | 4.71 | 4.73 | 4.73 | 22.79 | 15.39 | 0.5098 | 3.45 | 6.35 | 1,632,671.00 | 10.58 | 5.26 | 13.63 | 6.38 | 78.29 | 78.47 | 20.76 | 12.54 | 1.23 | 7.80 | 0.5667 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Pfizer Inc | 62.46bn | 7.87bn | 139.75bn | 81.00k | 17.83 | 1.55 | 9.45 | 2.24 | 1.38 | 1.38 | 10.95 | 15.89 | 0.2911 | 1.46 | 5.47 | 771,148.10 | 3.68 | 7.45 | 4.49 | 9.43 | 74.57 | 69.10 | 12.64 | 20.37 | 0.9604 | 12.26 | 0.4066 | 64.22 | 6.84 | 9.10 | 275.82 | -5.27 | 2.32 | 3.13 |
| Amgen Inc | 34.13bn | 5.93bn | 160.37bn | 28.00k | 27.22 | 25.84 | 13.90 | 4.70 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Merck & Co Inc | 63.92bn | 17.43bn | 204.70bn | 75.00k | 11.87 | 4.24 | 9.26 | 3.20 | 6.87 | 6.87 | 25.19 | 19.21 | 0.5786 | 2.31 | 5.77 | 852,293.30 | 15.79 | 9.52 | 20.46 | 12.64 | 77.07 | 73.47 | 27.30 | 17.87 | 1.16 | 23.90 | 0.4186 | 72.96 | 6.74 | 10.40 | 4,589.59 | 24.64 | -0.5885 | 6.66 |
| AbbVie Inc | 57.37bn | 4.16bn | 338.09bn | 55.00k | 81.61 | 238.08 | 26.81 | 5.89 | 2.35 | 2.35 | 32.39 | 0.804 | 0.4025 | 3.83 | 4.70 | 1,043,036.00 | 2.95 | 5.44 | 4.06 | 7.09 | 70.69 | 68.89 | 7.33 | 13.73 | 0.6359 | 7.80 | 0.9795 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 7.69 |
| Johnson & Johnson | 90.63bn | 22.66bn | 392.14bn | 138.10k | 17.43 | -- | 17.32 | 4.33 | 9.35 | 9.35 | 37.37 | -- | -- | -- | -- | 656,241.90 | -- | 8.63 | -- | 11.73 | 67.98 | 68.70 | 25.00 | 18.29 | -- | -- | -- | 74.74 | 4.30 | 1.60 | 5.55 | -1.43 | 4.81 | 5.54 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 222.87m | 9.26% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 133.79m | 5.56% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 129.14m | 5.36% |
| Geode Capital Management LLCas of 31 Mar 2025 | 59.38m | 2.47% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 34.85m | 1.45% |
| State Farm Investment Management Corp.as of 31 Mar 2025 | 31.68m | 1.32% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 30.36m | 1.26% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2025 | 26.26m | 1.09% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2025 | 24.07m | 1.00% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2025 | 22.65m | 0.94% |
